Denali stops some work on ALS drug after analysis showed no impact on key biomarker

Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for FDA approval after a failed topline readout earlier this year. The company is discontinuing DNL343 in that ...